RTP Mobile Logo
Select Publications

John N Allan, MD

Ghia P et al. First-line treatment with ibrutinib (ibr) plus venetoclax (ven) for chronic lymphocytic leukemia (CLL): 2-year post-randomization disease-free survival (DFS) results from the minimal residual disease (MRD) cohort of the phase 2 CAPTIVATE study. ASH 2021;Abstract 68.

Kater A et al. Fixed-duration ibrutinib and venetoclax (I+V) versus chlorambucil plus obinutuzumab (Clb+O) for first-line (1L) chronic lymphocytic leukemia (CLL): Primary analysis of the phase 3 GLOW study. EHA 2021;Abstract LB1902.

Wierda WG et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: Primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol 2021;39(34):3853-65. Abstract

Nitin Jain, MD

Byrd JC et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. ASCO 2021;Abstract 7500.

Cherng HJ, Jain N. First-line therapy for chronic lymphocytic leukemia: Bruton tyrosine kinase or BCL2 or both? Hematol Oncol Clin North Am 2021;35(4):725-38. Abstract

Hillmen P et al. First interim analysis of ALPINE study: Results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. EHA 2021;Abstract LB1900.

Anthony R Mato, MD, MSCE

Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 4-year follow-up analysis of the randomized CLL14 study. EHA 2021;Abstract S146.

Barr PB et al. Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. ASCO 2021;Abstract 7523.

Sharman J et al. Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: ELEVATE-TN 4-year follow-up. EHA 2021;Abstract S148.

John M Pagel, MD, PhD

Byrd JC et al. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: Final analysis of the pivotal phase Ib/II PCYC-1102 study. Clin Cancer Res 2020;26(15):3918-27. Abstract

Lin VS et al. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood 2020;135(25):2266-70. Abstract

Thompson MC et al. Venetoclax re-treatment of chronic lymphocytic leukemia (CLL) patients after a previous venetoclax-based regimen. ASH 2020;Abstract 3136.

Jennifer Woyach, MD

Long M et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest 2017;127(8):3052-64. Abstract  

Mato AR et al. Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study. ASH 2021;Abstract 391.

Siddiqi T et al. Updated follow-up of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma treated with lisocabtagene maraleucel in the phase 1 monotherapy cohort of TRANSCEND CLL 004, including high-risk and ibrutinib-treated patients. ASH 2020;Abstract 546.